A collaborative venture bringing together experts in bladder cancer and drug development
Chief Executive Officer
As CEO of CicloMed LLC, Ms. Ham leads a team of experts committed to developing and commercializing an innovative, less-invasive approach to fighting bladder cancer. Since 2015 she has served as President of CicloMed’s parent company, BioNovus Innovations LLC, which is building a portfolio of organizations to advance scientific discoveries into transformational improvements in healthcare. Ms. Ham started her career as a Registered Nurse in hospitals and outpatient settings, then became a clinical administrator. In 1997, she founded Ambulatory Surgery Assistance, Inc., which developed more than 30 ambulatory surgery centers. After selling that company to Nueterra Healthcare in 2005, Ms. Ham served in increasingly responsible executive roles with Nueterra. She is a Registered Nurse graduate of Saint Luke’s College of Nursing. Ms. Ham also serves as a mentor with Techstars and a board member of Operation Breakthrough.
William McCulloch, M.B., Ch.B., F.R.C.P., F.F.P.M.
Acting Chief Medical Officer and Chair of the Clinical Advisory Board
Dr. McCulloch brings to his role as CicloMed’s Chief Medical Officer more than three decades of experience in pharmaceutical research and development, as an executive and consultant to large and small companies focusing on cancer and serious infectious diseases. He has undertaken all phases of drug and technology development, and has been directly involved in filing INDs and NDAs, securing Orphan Drug status for compounds, and obtaining SBIR and other grant funding. As co-founder and president of Alba BioPharm Advisors since 2002, Dr. McCulloch has provided consulting services in drug development, oncology and regulatory affairs for clients. He earned his medical degree at the University of Glasgow and practiced medicine in the United Kingdom for seven years before entering the industry.
Scott J. Weir, Pharm.D., Ph.D.
Acting Chief Scientific Officer
Dr. Weir brings 32 years of drug discovery and development experience to CicloMed. He is a professor at the University of Kansas Medical Center, Director of the Institute for Advancing Medical Innovation (IAMI) at KU, and Associate Director of Translational Research for The University of Kansas Cancer Center. He is a co-discoverer of Ciclopirox Prodrug, the anticancer agent that CicloMed is developing. Since joining KU in 2006, Dr. Weir has established and managed a fully integrated program to discover promising new agents for the treatment and prevention of cancer, and to advance potential new drugs discovered at the university from bench to bedside. From 1986 to 2006, Dr. Weir served in leadership positions in several global pharmaceutical companies, contributing to successful development and regulatory approvals for a number of drug products. He earned his Pharm.D. degree from the University of Nebraska College of Pharmacy, followed by a Ph.D. in pharmacokinetics and biopharmaceutics from the University of Nebraska Medical Center.